BACKGROUND Long-acting injectable formulations of antipsychotics are treatment alternatives to oral agents. AIMS To assess the efficacy of aripiprazole once-monthly compared with oral aripiprazole for maintenance treatment of schizophrenia. METHOD A 38-week, double-blind, active-controlled, non-inferiority study; randomisation (2:2:1) to aripiprazole once-monthly 400 mg, oral aripiprazole (...

Aripiprazole, a novel antipsychotic agent, is assumed to be a “dopamine-serotonin system stabilizer”. According to preclinical studies, aripiprazole exerts partial agonistic action on D2 and 5-HT1A receptors. Thus, it may block a receptor if it is overstimulated and stimulate a receptor when activity is needed. It also has antagonist properties at 5-HT2A receptors. In randomized double-blind st...

This 24-week, open-label, Phase Ib, parallel-arm, multiple-dose trial assessed the pharmacokinetics, safety and tolerability of a once-monthly injection of aripiprazole (aripiprazole once-monthly) in 41 subjects with schizophrenia. The objective was to determine if aripiprazole plasma concentrations (at doses of 200, 300 and 400mg) were within the therapeutic range observed for the oral tablet ...

Aripiprazole is the first next-generation atypical antipsychotic with a mechanism of action that differs from currently marketed typical and atypical antipsychotics. Aripiprazole displays properties of an agonist and antagonist in animal models of dopaminergic hypoactivity and hyperactivity, respectively. This study examined the interactions of aripiprazole with a single population of human D2 ...

objective(s): the aim of this work was to investigate the effect of the natural and the chemically modified form of cyclodextrins namely; β-cyclodextrin (β-cd) and hydroxypropyl-β-cyclodextrin (hp-β-cd) respectively on the solubility and dissolution rate of aripiprazole; an antipsychotic medication showing poor aqueous solubility.   materials and methods: phase solubility of aripiprazole with t...

Hyperprolactinemia is a frequent consequence of treatment with risperidone. Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Thus, we examined the dose effects of adjunctive treatment with aripiprazole on the plasma concentration of prolactin in patients who had elevated prolactin levels because of risperidone treatme...

A 50-year-old male patient with comorbid human immunodeficiency virus developed a relapse of bipolar disorder after a switch from oral aripiprazole 10 mg/day to intramuscular aripiprazole depot 200 mg every 28 days plus oral aripiprazole 5 mg/day. The patient was concomitantly taking lopinavir, saquinavir, ritonavir, silybum marianum extract, and omeprazole. Only 1 week after the switch, the pa...

Aripiprazole is a third‐generation atypical (novel) antipsychotic, dihydroquinolinone, famously known as dopamine stabilizer, uniquely D2/D3 partial agonist, and 5HT1A agonist. It is a Food and Drug Administration‐approved drug for schizophrenia, bipolar mood disorder, augmentation in unipolar depression, irritability in autism, and Tourette syndrome in pediatric age group. It is lauded for bei...

CONTEXT Anxiety disorders are chronic, common, and often comorbid. There is an unmet need in its treatment. Aripiprazole and hydroxyzine are well-known therapeutic options used as monotherapy in clinics. They have different mechanisms and site of actions. AIM The objective of the present study was to evaluate the anxiolytic effect of aripiprazole and hydroxyzine in combination. MATERIALS AN...

BACKGROUND Several studies have evaluated the efficacy and tolerability of aripiprazole for augmentation of antidepressant therapy for treatment-resistant depression (TRD). Here, we investigated the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder and the clinical predictors of treatment efficacy in a Japanese population. METHODS Eigh...